Entry into cell cycle is mediated by CDK4/6 activation, followed by CDK2 activation. We found that pharmacological inhibition of the Flt3 internal tandem duplication (ITD), a mutated receptor tyrosine kinase commonly found in AML patients, led to the downregulation of Cyclin D2 and D3 followed by pRb dephosphorylation and G1 cell cycle arrest. This implicated the D-Cyclin-CDK4/6 complex as a downstream effector of Flt3 ITD signaling. Indeed, single agent PD 0332991, a selective CDK4/6 inhibitor, caused sustained cell cycle arrest in Flt3 ITD AML cell lines, and prolonged survival in an in vivo model of Flt3 ITD AML. PD 0332991 caused an initial cell cycle arrest in well-established Flt3 wildtype (wt) AML cell lines, but this was overcome by downregulation of p27Kip and reactivation of CDK2. This acquired resistance was not observed in a Flt3 ITD and a Flt3 wt primary AML patient sample. In summary, the mechanism of cell cycle arrest following treatment of Flt3 ITD AML with a FLT3 inhibitor involves downregulation of Cyclin D2 and D3. As such, CDK4/6 can be a therapeutic target in Flt3 ITD AML, but also in primary Flt3 wt AML. Finally, acquired resistance to CDK4/6 inhibition can arise through activation of CDK2.
Introduction
Acute myeloid leukemia (AML) is a heterogeneous disease at both the cytogenetic and molecular level. Many of these alterations have prognostic impact on clinical outcome and some also dictate therapeutic approaches 1 . Approximately 25% of patients express a constitutively active Flt3 internal tanden duplication (ITD), a mutant form of the receptor tyrosine kinase Flt3. The Flt3
ITD is a marker for poor prognosis 2, 3 . The availability of cell lines expressing Flt3 ITD as well as Flt3 inhibitors has made it possible to study the signaling pathways activated by mutant Flt3. Flt3
ITD signaling regulates a multitude of proteins involved in proliferation, differentiation and survival reflecting a complex signaling network that promotes oncogenesis [4] [5] [6] [7] [8] [9] [10] . It has also been reported that the pharmacologic inhibition of Flt3 ITD leads to cell cycle arrest but the underlying molecular mechanism and functional significance of this observation remains unclear 11, 12 .
Progression through the cell cycle from G1/G0 to S, G2 and M is initiated by CDK4 and the highly homologous enzyme CDK6. CDK4 and CDK6 form a complex with one of their activating subunits which are the Cyclins D1, D2 and D3 [13] [14] [15] . The activity of CDK4/6 is negatively regulated by the INK4 proteins 16 . The D-cyclin/CDK4/6 complex phosphorylates the retinoblastoma protein (pRb) and the related proteins p107 and p130 13, 15, 17 as well as Smad3 18 . In addition to being catalytically active, the Cyclin D-CDK4/6 complexes can also sequester the cell cycle inhibitors p21Cip1 and p27Kip1. This promotes the activation of the Cyclin E-CDK2 complex 19 which further phosphorylates pRb. Hyperphosphorylated pRb loses its inhibitory effect on the E2F transcription factor family. As a result of E2F activation the transcription of genes promoting entry into S-phase is initiated 20 . Here we show that the Flt3 ITD activates the Cyclin D, CDK4/6, INK4, pRb pathway by upregulating Cyclin D2 and D3 gene expression and that this pathway may constitute a drug target in AML.
For personal use only. on April 14, 2017 . by guest www.bloodjournal.org From 5 3% BSA, and probed with an anti-phospho-tyrosine antibody (4G10, Upstate Biotechnology, NY) overnight at 4°C. Subsequently, the blot was washed with PBS/ 0.1% Tween 20 and specific antibody binding was detected with a horseradish peroxidase-coupled secondary antibody, followed by enhanced chemiluminescence (ECL, Amersham Biosciences) and exposure to film.
To reprobe the blot, the primary antibody was stripped with ImmunoPure IgG Elution Buffer (Pierce).
For Western blots not involving immunoprecipitation, cells were centrifuged, the pellet was resuspended in PBS (10 µL/ 1X10 5 cells) and an equal volume of 2X Laemmli sample buffer was added to lyse the cells. The lysate was heated at 95°C for 10 minutes followed by centrifugation at 13,200 rpm. Typically, 20 µl of lysate were loaded on a gel for SDS/PAGE. The proteins were transferred to a nitrocellulose membrane as described above. For immunoblotting, the following antibodies were used: Using the pRb signal on the film of a Western Blot, densitometry was used to quantify the percentage of dephosphorylated pRb versus total pRb.
Kinase Assay. Cells were treated with DMSO or PD 0332991 (500 nM) for 24 hours or 96
hours. The cells were centrifuged, washed with ice-cold PBS and then lysed for 10 minutes in icecold lysis buffer (20 mM Tris pH 7.5, 1 mM EDTA, 150 mM NaCl, 0.5% NP40) which contained a protease inhibitor cocktail (Roche Diagnostics) and 1 mM sodium orthovanadate, 10 mM sodium fluoride, 10 mM β-glycerophosphate. Lysates were cleared by centrifugation at 13,000 x g for five minutes at 4°C. Cell Proliferation and Viability. Single agent effects on cell proliferation and viability were assessed by using the 3-(4,5-dimethylthaizol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Roche). The drug combination studies were also performed using the MTT assay. The analysis was executed with an in-house spreadsheet according to the median-effect method introduced by
Chou and Talalay 22 and as described previously 23 .
Flow Cytometry. Cell Cycle Analysis: Logarithmically growing cells were incubated with THRX-165724, PD 0223991 or DMSO (vehicle control) for the indicated periods of time. The cells were washed in ice-cold PBS and fixed in 70% ethanol. Subsequently, the cells were stained with PI staining buffer (propidium iodide 0.05 mg/ml, Sigma-Aldrich, 0.1% RNase, Invitrogen)
for 30 min at room temperature. The analysis was performed by flow cytometry.
Real-Time PCR.
cDNA was synthesized from 500 ng total RNA using Superscript III reverse transcriptase (Invitrogen) with oligo dT and p27Kip1 gene specific primers. cDNA products were quantitated by using SYBR green fluorescence on an AB7000 thermal cycler (Applied Immunohistochemistry. Sections of formalin-fixed, decalcified, paraffin-embedded tissues were mounted on Plus slides (Fisher). Slides were deparaffinized and antigen retrieval (DAKO TRS solution, 20 min in steamer, 20 min cooling to room temperature) was performed.
Peroxidase and protein blocking was carried out using blocking solutions from DAKO as directed. Primary antibodies were applied for 30 min at dilutions of 1:100 for phospho-pRb (pSer807/11) and 1:250 for human CD45. Appropriate secondary antibodies were from Vector Elite kits. They were incubated with the sections for 30 min. The chromagen was DAB and sections were lightly counterstained with hematoxylin. After dehydration, coverslips were applied using a xylene-based mounting medium. 24 and SU14813 25 , inhibitors of the PDGFR receptor family which includes Flt3, were used as pharmacological tools ( Figure   1A ). It follows that the reduction of Cyclin D2 and D3 protein leads to the reduction of CDK4/6 activity 26 . pRb is known to be hyperphosphorylated when CDK4/6 is active, so the loss of CDK4/6 activity leads to the dephosphorylation of pRb 26 which is reflected in a shift of the apparent molecular weight of the protein. We found that at 4 hours after the start of THRX-165724 treatment, as Cyclin D2 and D3 levels decrease, pRb phosphorylation also decreases. At 12 hours, when Cyclin D2 and D3 levels are very low, pRb is almost completely dephosphorylated. The THRX-165724 mediated downregulation of Cyclin D2 and D3 as well as the dephosphorylation of pRb was also observed in Flt3 ITD MOLM13 cells (Supplemental Figure 3 ). THRX-165724 had no effect on the D-Cyclin protein level and pRb phosphorylation status in the Flt3 wt cell lines THP-1 and U937 ( Figure 2D ). Like THRX-165724, the second Flt3 inhibitor, SU14813, induced the downregulation of Cyclin D2 and D3 as well as pRb dephosphorylation in MV4-11 and MOLM13 (Flt3 ITD) but not in THP-1 and U937 (Flt3 wt) ( Figure 2D ). These data suggest that CDK4/6 is activated by Flt3 ITD signaling through the upregulation of Cyclin D2 and D3, and that inhibition of the Flt3 ITD inhibits activation of
PD 0332991 is a potent CDK4/6 inhibitor. In order to evaluate the role of CDK4/6 in the AML cell lines, we used PD 0332991, a small molecule inhibitor of CDK4/6 that is currently in phase II clinical trials ( Figure 3A) . PD 0332991 has little or no activity against a panel of 30 kinases, including CDK2, suggesting that this inhibitor is highly selective for CDK4/6 27, 28 . Importantly, we found that at 500 nM, PD 0332991 has no effect on Flt3 ITD autophosphorylation which makes this compound a suitable tool to study CDK4/6 in our AML model system ( Figure 3B ).
We incubated Flt3 ITD(+) MV4-11 and MOLM13 cells with increasing concentrations of PD 0332991. A Western Blot of cell lysates showed decreasing pRb phosphorylation, confirming CDK4/6 inhibition by PD 0332991 ( Figure 3C ). The IC50 of PD 0332991 in this assay in both cell lines is 30 nM.
We next tested the effect of PD 0332991 on the cell cycle of our model cell lines after an incubation period of 24 hours and 120 hours. Figure 4A demonstrates that MOLM13 cells (Flt3 ITD positive) are strongly arrested in G1 at 24 and 120 hours. Furthermore, a sub-G1 peak at 120
For personal use only. on April 14, 2017. by guest www.bloodjournal.org From hours suggests that some cells are undergoing apoptosis. In contrast, U937 cells (Flt3 wt) were arrested in G1 at the 24 hour time point but these cells had reentered the cell cycle after 120 hours. Like MOLM13, the Flt3 ITD positive MV4-11 cell line was arrested in G1 at 24 and 120 hours whereas Flt3 wt THP-1 cells were arrested in G1 at the 24 hour time point but had reentered the cell cycle at 120 hours ( Figure 4B ). However, despite reentering the cell cycle, PD 0332991 treated THP-1 and U937 were still showing significantly fewer cells in S and G2 of the cell cycle than the respective control cells. As expected, the effect of PD 0332991 on the cell cycle also led to an effect on proliferation ( Figure 4C ). MOLM13 and MV4-11 cells incubated with PD 0332991 as a single agent for eight days decreased in cell number, and although THP-1 and U937 cell numbers increased, the increase was considerably smaller than for the same cells incubated with the vehicle control. Hence, the inhibition of entry into the cell cycle and proliferation in these well-established Flt3 wt AML cell lines is only partial, consistent with an acquired mechanism of resistance to PD 0332991 following prolonged exposure as a single agent. 
in all four cell lines. Interestingly, after four days of incubation with PD 0332991, the CDK2 inhibitor p27Kip1 was strongly downregulated in Flt3 wt THP-1 and U937.
Furthermore, in U937 Cyclin E was upregulated. In contrast, no significant changes in the protein level of p27Kip1 and Cyclin E were observed in Flt3 ITD MOLM13 and MV4-11 ( Figure 5B ).
These data led us to hypothesize that after treatment with PD 0332991 for multiple days, the selective downregulation of p27Kip1 in FLT3 wild type THP-1 and U937 cells is responsible for higher CDK2 activity than is seen in MOLM13 and MV4-11 cells. To test this hypothesis we performed a CDK2 in vitro kinase assay with cells treated for 24 hours and 96 hours with PD 0332991 ( Figure 5C ). After treatment for 24 hours, CDK2 kinase activity was reduced in all cell lines suggesting that CDK2 activation is dependent on CDK4/6 activity at this early time point.
At the 96 hour time point, however, CDK2 activity in THP-1 and U937 cells was restored.
p27Kip1 transcription can be promoted by the transcription factor Foxo3a and the phosphorylation of Foxo3a leads to its inactivation [29] [30] [31] [32] . We found, however, no changes in Foxo3a phosphorylation status in any of the four AML cell lines treated for 96 hours with PD 0332991 ( Figure 5D ). We used mRNA prepared from cells of the same experiment to perform a
Real-Time PCR analysis to detect changes in p27Kip1 transcript levels. We applied two different sets of p27Kip1 specific primers for this experiment. This experiment showed p27Kip1 mRNA is modestly reduced between 2-3 fold in THP-1, U937 and MOLM13 cells treated with PD 0332991. There was no significant change of p27Kip1 transcript levels in MV4-11 cells. Figure 7A demonstrates that CD45 cells from mice treated with PD 0332991 showed a significant reduction in pRb phosphorylation as compared to CD45 cells from mice treated with buffer as a control. Hence, the compound is active in the desired cell population in vivo. In the subsequent aggressive survival experiment we found that single agent PD 0332991 could prolong the survival of NOD/SCID mice engrafted with MOLM13 by 4-5 days (p=0.0003) ( Figure 7B ).
In the final experiment we engrafted mice with MOLM13, treated the mice for five days starting on day five after engraftment and performed immunohistochemistry on the bone marrow. 
Staining with H&E and anti-human CD45 demonstrated the presence of MOLM13 cells in the

Discussion
This study began with a focus on the molecular basis by which pharmacologic inhibition of Flt3 ITD autophosphorylation antagonizes the entry into the cell cycle. We found that the inhibition of The ability to compensate at least partially for the pharmacological inhibition of CDK4/6 by using CDK2 may be one way for established AML cell lines to escape the anti-proliferative effect of an inhibitor like PD 0332991. We found it, however, encouraging that both the Flt3 ITD(+) and the Flt3 wt primary AML samples that we tested were sensitive to PD 0332991 and did not upregulate CDK2 activity following prolonged exposure. In the Flt3 ITD primary AML sample the observed cell cycle arrest, the pronounced dephosphorylation of pRb, and CDK2 downregulation in response to CDK4/6 inhibition are consistent with the observations noted in The partial dephosphorylation of pRb in CD34(+) cells (only 34% of pRb is dephosphorylated) could be due to incomplete inhibition of CDK4/6 by PD 0332991. However, since we treated the CD34(+) cells in parallel and under the same conditions as the strongly responding primary AML cells, we believe that the basis for the remaining pRb phosphorylation in CD34(+) cells is a result of compensatory CDK2 activity that we were able to measure by an in vitro kinase assay. are a distinct subset of the cyclin-dependent kinases that associate with cyclin D1.
Oncogene. 1994;9:71-79. Lysates were resolved by SDS-PAGE followed by immunobloting with anti-pRb. For personal use only. on April 14, 2017 . by guest www.bloodjournal.org From patient samples) (medium grey) or PD0332991 (500 nM) plus SU14813 (30 nM for cell lines and 100 nM for patient samples) (dark grey). The DMSO control is normalized to 100% (mean ± standard error of three independent experiments for the cell lines and one experiment with triplicate data points for the patient samples). E. Apoptosis assay. MV4-11, MOLM13, THP-1 and U937 cells were incubated for three days with DMSO (control), PD0332911 (250 nM) (light grey), SU14813 (100 nM) (medium grey) or PD0332991 (250 nM) plus SU14813 (100 nM) (dark grey). The DMSO control is normalized to 100%. The cells were stained with Annexin V-PE and 7-AAD followed by flow cytometric analysis (See Supplemental Figure 4 for primary data). 
